Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of NKTR-102 (PEG-irinotecan) Versus Irinotecan in Second-Line KRAS-Mutant Metastatic or Locally Advanced Colorectal Cancer
2008-004093-40Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Jan 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of etirinotecan pegol in colorectal cancer (CRC) (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-004093-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004093-40.